HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Philip W. Smith Benjamin D. Kozower Christine L. Lau David R. Jones Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Taylor, M. D. Articles by Jones, D. R. Search for Related Content PubMed Articles by Taylor, M. D. Articles by Jones, D. R. Related Collections Lung - cancer

J Thorac Cardiovasc Surg 2009;137:43-48
© 2009 The American Association for Thoracic Surgery

General Thoracic Surgery

Fluorodeoxyglucose positron emission tomography and tumor marker expression in non–small cell lung cancer

^a Department of Surgery, University of Virginia, Charlottesville, Va
^b Department of Pathology, University of Virginia, Charlottesville, Va

Received for publication June 24, 2008; revisions received September 18, 2008; accepted for publication October 13, 2008.

^_* Address for reprints: David R. Jones, MD, Professor of Surgery, University of Virginia, Department of Surgery, Box 800679, Charlottesville, VA 22908-0679. (Email: djones{at}virginia.edu).

Objective: The best current noninvasive surrogate for tumor biology is fluorodeoxyglucose positron emission tomography (FDG–PET). Both FDG–PET maximal standardized uptake values and selected tumor markers have been shown to correlate with stage, nodal disease, and survival in non–small cell lung cancer (NSCLC). However, there are limited data correlating FDG–PET with tumor markers. The purpose of this study was to determine the correlation of tumor marker expression with FDG–PET maximal standardized uptake values in NSCLC.

Methods: FDG–PET maximal standardized uptake values were calculated in patients with NSCLC (n = 149). No patient had induction chemoradiotherapy. Intraoperative NSCLC tissue was obtained and tissue microarrays were created. Immunohistochemical analysis was performed for 5 known NSCLC tumor markers (glucose transporter 1, p53, cyclin D1, epidermal growth factor receptor, and vascular endothelial growth factor). Each tumor marker was assessed independently by two pathologists using common grading criteria. Subgroup analysis based on histologic characteristics and regional nodal status was performed.

Results: FDG–PET correlated with T classification (P < .0001), N stage (P = .002), and greatest tumor dimension (P < .0001). In addition, increasing maximal standardized uptake values correlated with increased expression of glucose transporter 1 (P < .0001) and p53 (P = .04) in adenocarcinoma. Epidermal growth factor receptor expression correlated with maximal standardized uptake values without predilection for histologic subtype (P = .004).

Conclusion: FDG–PET maximal standardized uptake values correlate with an increased expression of glucose transporter 1 and p53 in lung adenocarcinoma, but not squamous cell cancer. Future studies attempting to correlate FDG–PET with tumor biology will need to consider the effect of different tumor histologic types.